索格列净对心衰恶化患者健康状况的影响:SOLOIST-WHF 研究结果
SOLOIST-WHF 试验预设分析评估索格列净与安慰剂对心衰相关健康状况的影响,1,113 例患者有基线与 4 个月 KCCQ-12 数据。索格列净组 4 个月 KCCQ-12 校正平均改善 4.1 分(95%CI 1.3-7.0,P=0.005),≥5 分改善比例更高(OR 1.38,95%CI 1.06-1.80,P=0.017),且主要终点风险降低在各 KCCQ-12 三分位间一致。
要点
- 索格列净在 4 个月内小幅改善心衰恶化患者的症状与生活质量。
- KCCQ-12 改善在 LVEF<50% 或≥50% 等亚组中一致。
- 主要终点获益不随基线 KCCQ-12 三分位变化。
核心结论
- 索格列净在改善心衰后 4 个月内改善症状、体力受限与生活质量,且获益在基线人口学与临床特征间一致。
研究设计与样本
- SOLOIST-WHF 试验预设分析,患者因心衰恶化住院或近期出院后随机接受索格列净或安慰剂。
- 1,222 例随机患者中 1,113 例(91%)有基线与 4 个月完整 KCCQ-12 数据。
主要发现
- 基线 KCCQ-12 评分整体较低(中位数 41.7,Q1-Q3 27.1-58.3),两组 4 个月均改善。
- 索格列净组 4 个月 KCCQ-12 校正平均变化 4.1 分(95%CI 1.3-7.0,P=0.005)。
- 索格列净组达到至少小幅(≥5 分)KCCQ-12 改善的患者更多(OR 1.38,95%CI 1.06-1.80,P=0.017)。
- 主要终点风险降低在各 KCCQ-12 三分位间一致(Ptrend=0.54)。
- KCCQ-12 改善在预设亚组(包括 LVEF<50% 或≥50%)中一致。
临床怎么用
- 对心衰恶化住院或近期出院患者,可考虑索格列净以改善 4 个月内症状与生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the effects of SGLT1 and SGLT2 inhibition on health status are unknown. OBJECTIVES: These prespecified analyses of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial examined the effects of sotagliflozin vs placebo on HF-related health status. METHODS: SOLOIST-WHF randomized patients hospitalized or recently discharged after a worsening HF episode to receive sotagliflozin or placebo. The primary endpoint was total number of HF hospitalizations, urgent HF visits, and cardiovascular death. Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score was a prespecified secondary endpoint. This analysis evaluated change in the KCCQ-12 score from baseline to month 4. RESULTS: Of 1,222 patients randomized, 1,113 (91%) had complete KCCQ-12 data at baseline and 4 months. The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups. Sotagliflozin vs placebo reduced the risk of the primary endpoint consistently across KCCQ-12 tertiles (Ptrend = 0.54). Sotagliflozin-treated patients vs those receiving placebo experienced modest improvement in KCCQ-12 at 4 months (adjusted mean change: 4.1 points; 95% CI: 1.3-7.0 points; P = 0.005). KCCQ-12 improvements were consistent across prespecified subgroups, including left ventricular ejection fraction <50% or ≥50%. More patients receiving sotagliflozin vs those receiving placebo had at least small (≥5 points) improvements in KCCQ-12 at 4 months (OR: 1.38; 95% CI: 1.06-1.80; P = 0.017). CONCLUSIONS: Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934).
引用
- Bhatt, Bhatt, Steg, et al. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF. J Am Coll Cardiol. 2024. PMID: 39260929. doi:10.1016/j.jacc.2024.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。